Developed in the 1980s, BTG's recombinant human growth hormone (somatropin for injection or hGH) first gained regulatory approval in 1988. It is identical to natural human growth hormone synthesized by the pituitary gland, and is used to treat growth hormone deficiency in children and in Turner syndrome. In 2009, our company received a development award from the Chief Scientist of Israel’s Ministry of Trade and Industry in recognition of its achievement in the development and commercialization of hGH.
Finished products containing BTG's recombinant hGH are approved and sold in more than 40 countries, including Israel, the United States, Europe and Japan. hGH finished products manufactured by BTG/Ferring are marketed in Israel under the trade name Bio-Tropin®, in Europe and elsewhere under the trade name ZOMACTON® and in the United States under the trade name TEV-TROPIN® by Teva Pharmaceuticals Inc. Finished products containing BTG’s recombinant hGH are manufactured and sold in Japan under the trade name Growject by JCR Pharmaceuticals Co. Ltd., and are manufactured and marketed in Mexico under the trade name Cryotropin by Laboratorios Cryopharma S.A. de C.V.
For more information please visit http://www.ferring.com/en/therapeutic-areas/endocrinology.aspx
Please note that product information presented on this website is intended only as a brief summary for the visitor's convenience in relation to the activities of the Ferring Group. Not all products or indications are licensed in every country and may be subject to further local variations. For advice on medical issues please consult your local medical practitioner.